219 related articles for article (PubMed ID: 35653982)
1. Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis.
Nader-Marta G; Martins-Branco D; Agostinetto E; Bruzzone M; Ceppi M; Danielli L; Lambertini M; Kotecki N; Awada A; de Azambuja E
ESMO Open; 2022 Jun; 7(3):100501. PubMed ID: 35653982
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine kinase inhibitors in HER2-positive breast cancer brain metastases: A systematic review and meta-analysis.
Yu Y; Huang K; Lin Y; Zhang J; Song C
Cancer Med; 2023 Jul; 12(14):15090-15100. PubMed ID: 37255389
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. Real-world data of pyrotinib-based therapy for patients with brain metastases of HER2-positive advanced breast cancer: a single-center retrospective analysis and molecular portraits.
Wang H; Liu Q; Zhang M; Zhang J; Ran R; Ma Y; Yang J; Wang F; He S; Zhao X; Wang L; Zhang L; Dong D; Yang J
Front Oncol; 2023; 13():1105474. PubMed ID: 37397372
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review.
Yuan Y; Liu X; Cai Y; Li W
PLoS One; 2023; 18(1):e0279775. PubMed ID: 36602979
[TBL] [Abstract][Full Text] [Related]
6. A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
Larsen PB; Kümler I; Nielsen DL
Cancer Treat Rev; 2013 Nov; 39(7):720-7. PubMed ID: 23481218
[TBL] [Abstract][Full Text] [Related]
7. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
8. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis.
Li J; Huo X; Zhao F; Ren D; Ahmad R; Yuan X; Du F; Zhao J
JAMA Netw Open; 2020 Oct; 3(10):e2020312. PubMed ID: 33048129
[TBL] [Abstract][Full Text] [Related]
9. Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study.
Hua Y; Li W; Jin N; Cai D; Sun J; Sun C; Yang F; Wu X; Huang X; Wang B; Yin Y
Ther Adv Med Oncol; 2022; 14():17588359221085232. PubMed ID: 35356262
[TBL] [Abstract][Full Text] [Related]
10. Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data.
Anwar M; Chen Q; Ouyang D; Wang S; Xie N; Ouyang Q; Fan P; Qian L; Chen G; Zhou E; Guo L; Gu X; Ding B; Yang X; Liu L; Deng C; Xiao Z; Li J; Wang Y; Zeng S; Hu J; Zhou W; Qiu B; Wang Z; Weng J; Liu M; Li Y; Tang T; Wang J; Zhang H; Dai B; Tang W; Wu T; Xiao M; Li X; Liu H; Li L; Yi W
Clin Cancer Res; 2021 Aug; 27(16):4634-4641. PubMed ID: 34112711
[TBL] [Abstract][Full Text] [Related]
11. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
12. The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.
Le Du F; Diéras V; Curigliano G
Eur J Cancer; 2021 Sep; 154():175-189. PubMed ID: 34280871
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis.
Yang F; Zhang W; Shang X; Liu N; Ma X; Qin J; Zhang Y; Liu Y; Wang X
Crit Rev Oncol Hematol; 2022 Sep; 177():103760. PubMed ID: 35870763
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
15. Brain Metastases Status and Immunotherapy Efficacy in Advanced Lung Cancer: A Systematic Review and Meta-Analysis.
Hu H; Xu ZY; Zhu Q; Liu X; Jiang SC; Zheng JH
Front Immunol; 2021; 12():669398. PubMed ID: 34335570
[TBL] [Abstract][Full Text] [Related]
16. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-containing regimens for metastatic breast cancer.
Balduzzi S; Mantarro S; Guarneri V; Tagliabue L; Pistotti V; Moja L; D'Amico R
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD006242. PubMed ID: 24919460
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study.
Ouyang DJ; Chen QT; Anwar M; Xie N; Ouyang QC; Fan PZ; Qian LY; Chen GN; Zhou EX; Guo L; Gu XW; Ding BN; Yang XH; Liu LP; Deng C; Xiao Z; Li J; Wang YQ; Zeng S; Wang S; Yi W
Front Pharmacol; 2021; 12():682568. PubMed ID: 34512325
[No Abstract] [Full Text] [Related]
19. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis.
Petrelli F; Ghidini M; Lonati V; Tomasello G; Borgonovo K; Ghilardi M; Cabiddu M; Barni S
Eur J Cancer; 2017 Oct; 84():141-148. PubMed ID: 28810186
[TBL] [Abstract][Full Text] [Related]
20. Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis.
Werter IM; Remmelzwaal S; Burchell GL; de Gruijl TD; Konings IR; van der Vliet HJ; Menke-van der Houven van Oordt CW
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
